Although 3 generations of EGFR-TKIs are currently available for the treatment of EGFR mutation-positive NSCLC, the optimal sequence of administrating these drugs to maximize the duration of the EGFR signaling inhibition remains still uncertain15,16. This evidence concerns the gene EGFR and non-small cell lung carcinoma.